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http://dx.doi.org/10.1016/j.jfma.201Statins [3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase], are wonder drugs that
have reshaped the treatment of hypercholesterolemia and associated cardiovascular diseases.
However, evidence from various studies indicates existence of many statin-induced side ef-
fects such as myopathies, rhabdomyolysis, hepatotoxicity, peripheral neuropathy, impaired
myocardial contractility, diabetes, autoimmune diseases, and erectile dysfunction (ED). Physi-
cian awareness of these side effects is reported to be very low even for the adverse effects
(AEs) most widely reported by patients. This can lead to incorrect treatment decisions,
compromised patient care, and an increase in patient morbidity. Therefore, the aim of this
article is to highlight the AEs of statin therapy as well as rational management of these com-
plications to further improve safety of these excellent drugs.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Statins are drugs that inhibit 3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase, thereby blocking the
synthesis of cholesterol. The first statin (Compactin, later
renamed as Mevastatin) was discovered in the 1970s by a
research group headed by a young scientist, Akira Endo,
working at Sankyo Pharmaceuticals in Tokyo.1 This discov-
ery led to the development of a series of HMG Co A
reductase inhibitors. Currently available statins may be1004, Antariksh Greens, Plot
ization, Sector 45, Gurgaon,
il.com (S. Luthra).
ight ª 2013, Elsevier Taiwan LLC
3.05.016classified into two groups. Fermentation-derived statins
include simvastatin and pravastatin, whereas atorvastatin,
cerivastatin, fluvastatin, pitavastatin, and rosuvastatin are
synthetic statins.
The Scandinavian Simvastatin Survival Study (4S) trial in
1994 showed that statins help in the prevention of cardio-
vascular events associated with increased blood lipids and
atherosclerotic lesions.2 With coronary heart disease being
one of the most common causes of death worldwide, statins
are proven lifesaving medications. Most clinical trials such
as Long-term Intervention with Pravastatin in Ischemic
Disease (LIPID) and the Heart Protection Study (HPS) re-
ported a significant reduction in relative risk of coronary
events versus placebo. Besides lipid lowering action, statins
also possess multiple pleiotropic actions such as anti--
inflammation,3e5 immunomodulatory,6 antioxidant,7& Formosan Medical Association. All rights reserved.
Adverse effects of statins 893antithrombotic,8 plaque stability,9 angiogenesis promo-
tion,10 and increase in bone formation11 (Table 1). 3e11
Many other new pleiotropic effects of statins are continu-
ously being described but their clinical relevance has not
been established. Most of them are added to the long list of
beneficial effects without being critically evaluated. Only a
few investigators regard some of the pleiotropic effects as
controversial or of adverse consequence, accounting in part
for the side effects of statins. In relation to this, a short
analysis at the University of California, San Francisco
concluded that 96% of authors with drug company ties
declared statins to be safe versus 37% authors with no
ties.12 Similar results were also expressed by Taylor et al in
a Cochrane Review in 2011.13
The incidence of myopathy in routine clinical practice is
much more frequent than in clinical trials because patients
in these trials are usually younger, free of accompanying
diseases, receive lower statin doses for shorter time pe-
riods, and are strictly monitored.14 In 2008, Golomb et al15
reviewed 900 studies proving their adverse effects (AEs),
which run the gamut from muscle problems to increased
cancer risk (Table 2).14,16e50 Statins inhibit the mevalonate
pathway, which not only inhibits cholesterol formation, but
also many other products such as coenzyme Q, iso-
prenylated protein, selenoproteins, and heme A that are
known to play a very important role in maintaining cell
biology and human physiology.15,51 The aim of this review
article is to emphasize the side effects of statins, their
mechanisms, and management, so as to further improve
the safety of these drugs.
Statin-induced myopathy
Muscular AEs are the most commonly reported AEs of sta-
tins. These range from muscle weakness, fatigue, pain, to
rhabdomyolysis. Various statins differ in their ability to
induce this complication. In August 2001, cerivastatin was
removed from European and US markets because of a
higher risk of rhabdomyolysis associated with its use inTable 1 Advantages of statins.
Advantages of statins Discussion
Anti-inflammatory Decrease basal and IL-1b-induce
Inhibits ICAM-1 upregulation and
Immunomodulatory Inhibits MHC II expression.
Binds to LFA and prevents its bi
Antioxidant Inhibition of production of NADP
Antithrombotic Inhibition of platelet aggregatio
between prothrombotic and fib
Plaque stability Inhibition of matrix metalloprot
Angiogenesis biphasic
action
Low statin doses induce a pro-a
and increase nitric oxide produc
decrease protein prenylation an
Bone formation Potent activator of BMP-2 by re
intermediates and inhibition of
BMP-2 Z bone morphogenetic protein; huCRP Z human C-rea
IL-1b Z interleukin-1b; LFA Z leucocyte function-associate
NADPH Z nicotinamide adenine dinucleotide phosphate.comparison with other statins. The estimated risk of
developing rhabdomyolysis is 0.3 per 100,000 person years,
with a fatality rate of 9%.16 The combination of any statin
with a fibrate increases the risks for rhabdomyolysis to
almost 6.0 per 100,000 person years.17
The organic anion transporter OATP1B1, an uptake
transporter of statins located on hepatocytes, is encoded
by the gene solute carrier organic anion transporter family
member 1B1 (SLCO1B1). A hetero- and homozygous poly-
morphism of this gene is associated with a 4- and 17-fold
increase in statin-induced myopathy, respectively.18 One of
the main predisposing factors for statin-related muscle
complaints is exercise and it can also be influenced by
mitochondrial dysfunction, membrane disruption, and/or
calcium handling.19 The Food and Drug Administration
(FDA) also recognizes some drug interactions associated
with intake of statin that can increase the risk for muscle
injury. For example, the use of protease inhibitors along
with lovastatin and simvastatin is contraindicated. It has
been suggested that statins induce apoptosis of skeletal
muscle cells by impairing prenylation-dependent processing
of prelamin to mature lamin A, which is an important
component of intermediate filament lamina involved in the
breakdown and reformation of the nuclear envelope during
mitosis, as well as the positioning of nuclear pores. Another
suggested mechanism is inhibition of glycosylation of
cytoskeletal protein dystroglycan or deficiency of relevant
compounds like mevalonate and ubiquinone (coenzyme
Q10, CoQ10) leading to mitochondrial dysfunction.
Statin-induced myopathy is a common dilemma not re-
flected in clinical trials. This may occur due to wide vari-
ation in the definitions of myopathy, which may lead to
difficulty in drawing reliable conclusions among studies and
to determine accurate diagnostic criteria. Also the magni-
tude of increase in creatinine kinase (CK) needed to define
rhabdomyolysis has increased from 500 IU/L to 1000 IU/L in
1988. Another reason for myopathy to be an uncommon
finding in clinical trials is that to minimize toxicity the
clinical trials of statins excluded patients with renalRefs
d plasma huCRP levels.
chemotaxis in adherent human monocytes.
3e5
nding to ICAM1.
6
H oxidase. 7
n and maintenance of favorable balance
rinolytic mechanisms.
8
einase 9. 9
ngiogenic effect through Akt activation
tion, whereas high statin doses may
d inhibit cell growth.
10
duction in mevalonate pathway
prenylated proteins.
11
ctive protein; ICAM-1 Z intercellular adhesion molecule-1;
d antigen; MHC-II Z major histocompatibility complex;
Table 2 Adverse effects (AEs) of statins.
AEs Discussion Refs
Myopathy Muscle weakness, fatigue, pain, rhabdomyolysis due to impairment of
prenylation-dependent processing of prelamin to mature lamin A, inhibition
of glycosylation of cytoskeletal protein dystroglycan, or deficiency of
relevant compounds like mevalonate and ubiquinone (CoQ10) leading to
mitochondrial dysfunction
16e21
Hepatotoxicity Statins induce caspase activation and trigger apoptosis of cultured human
hepatocytes
Reduction of CoQ10 level
Induction of oxidative stress in the liver
14,22
Nephrotoxicity Proteinuria due to renal tubular degeneration
Microalbuminuria, a predictor of cardiovascular and renal events due to the
decrease in megalin and cubulin receptors that results from the decrease in
mevalonate activity
23e25
Diabetes mellitus Risk of developing diabetes mellitus by inhibiting adipocyte maturation and
expression of insulin sensitive glucose transporter (GLUT 4) in vitro
Reduces glucose-induced insulin secretion by attenuating glucose-induced
increase in intracellular Ca2þ concentration in vitro
26e32
Neurologic manifestations Paresthesias, sensory loss, hyperesthesia of the extremities, areflexia,
muscle weakness, memory loss in extreme cases
16,33e36
Proinflammatory Release of proinflammatory markers such as IL-1b, IL-6, IL-12, and TNF-a
Associated with drug-induced lupus erythematosus and other autoimmune
disorders such as dermatomyositis, polymyositis, autoimmune hepatitis,
pemphigoides, and hypersensitivity pneumonitis
37e39
Pulmonary manifestations ILD
Progression of pulmonary fibrosis by enhancing secretion of inflammasome-
regulated cytokines
40,41
Ophthalmological
manifestations
Diplopia, ptosis, or ophthalmoplegia by myositis of the levator palpebrae
superioris muscles, extraocular muscles, or both
42
Cancer risk Increase in incidence of prostate cancer in men 43e46
Erectile dysfunction Statins can hamper adrenocortical function or steroidogenesis by blocking
cholesterol production
47e49
In oral cavity Dryness, itch, bitterness, and cough 50
CoQ10 Z coenzyme Q10; ILD Z interstitial lung disease; IL-1b Z interleukin-1b; IL-6 Z interleukin-6; IL-12 Z interleukin-12;
TNF-a Z tumor necrosis factor-a.
894 H.S. Grover et al.insufficiency, hepatic insufficiency, a history of muscular
complaints, and poorly controlled diabetes, as well as pa-
tients taking drugs with possible interactions.20
Monitoring serum CK level is not required but may be
useful in high-risk patients or those patients with nonspe-
cific symptoms. An estimation of CK serum level is needed
to confirm the diagnosis and assess the severity of muscle
damage. It is important to note that CK values may be
normal in patients with overt symptoms. In the absence of
other causes, persistent muscle complaints or CK elevation
should promptly be followed by discontinuation of the drug.
CK elevation more than 10 times its normal level indicates
rhabdomyolysis and such patients may need hospital
admission and supportive therapies. Discontinuation of
statins leads to complete resolution of symptoms usually
within 1 week to 4 months. Once full recovery is achieved,
other forms of statins can be tried. There is no specific
therapy to prevent or treat statin-induced myopathy.
However, some case reports of patients with statin myop-
athy described some improvement with the administration
of CoQ10.18 By contrast, there is insufficient evidence toprove that statin-induced myopathy is caused by deficiency
of CoQ10. Therefore, the routine use of CoQ10 in such cases
cannot be recommended. Nevertheless, there are no known
risks to this supplement. Consequently, CoQ10 can be
tested in patients who develop statin-induced myalgia, and
who cannot be satisfactorily treated with other agents.
Some patients may respond, if only via a placebo effect.21Hepatotoxicity
Dose-dependent elevation in liver enzymes, specifically
aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT), to greater than three times the upper normal
limit is seen in less than 1% of patients receiving statin as
initial treatment and in 1e3% of those on higher doses
(e.g., 80 mg atorvastatin).14 The mechanism of hepato-
toxicity of statins is incompletely clear. However, it has
been demonstrated that statins induce caspase activation
and trigger apoptosis of cultured human hepatocytes, along
with reduction of the CoQ10 level and induction of
Adverse effects of statins 895oxidative stress in the liver.14 Allen et al in 2012 reported
that miR-33, a micro-RNA, mediates some of the undesired,
hepatotoxic effects of statins. They also showed that
silencing miR-33 rescues the hepatotoxicity and lethality
caused by co-administration of simvastatin and a cholate-
rich diet.22
In 2012, the FDA recommended that liver enzyme tests
should be performed before starting statin therapy, and as
clinically indicated thereafter. It has recognized that
serious liver injuries are rare with the use of statin and
unpredictable in individual patients. Therefore, detection
or prevention of this rare AE with routine periodic moni-
toring of liver enzymes is ineffective. Patients should notify
their physician immediately if they develop the following
symptoms of liver problems: unusual fatigue or weakness;
loss of appetite; upper belly pain; dark-colored urine; yel-
lowing of the skin or the whites of the eyes.
Pretreatment elevation of serum transaminases does not
increase the risk of statin-induced hepatotoxicity and thus
is not a contraindication for therapy until additional fea-
tures of liver dysfunction, such as elevation of bilirubin,
prolongation of prothrombin time, etc., are also present.
Asymptomatic elevation of transaminases noted in a statin
user is not an indication to discontinue potentially life-
saving statin therapy and should first prompt the physician
to search for other causes of liver injury such as viral
hepatitis, alcohol consumption, or other drugs.14Nephrotoxicity
Various studies on statins have been shown to cause pro-
teinuria due to renal tubular degeneration at high doses.
Although this AE has long been recognized, the phenomenon
came into the limelight when clinical trials on rosuvastatin
were conducted. A high incidence of proteinuria and hema-
turia was seen along with isolated cases of renal failure,
some of which were associated with myopathy.52 The Pro-
spective Pravastatin Pooling Project, which included results
from three randomized clinical trials of pravastatin [West of
Scotland Coronary Prevention Study (WOSCOPS), Cholesterol
and Recurrent Events (CARE), and Long-term Intervention
with Pravastatin in Ischemic Disease (LIPID) Trial], found that
the rates of renal disease and failure were 0.8% and 0.5%,
respectively, and they were more frequently found in
pravastatin-treated patients than in patients taking pla-
cebo.23 Another study by Van der Tol et al in 2012 reported
that the use of statins was associated with micro-
albuminuria, a predictor or marker of cardiovascular and
renal events.24 The suggested mechanism of action is a
decrease in the megalin and cubulin receptors due to the
decrease in mevalonate activity. These receptors are
involved in the process of receptor-mediated endocytosis
that is responsible for albumin uptake in proximal tubular
cells.
It is not necessary to carry out serum creatinine and
proteinuria monitoring routinely to identify the AEs of statin
on the kidney. However, an assessment of renal function is
advisable before initiating statin therapy. If unexpected
proteinuria develops, there is no need to withdraw statin
therapy or to alter the dose of the statin. Although an
investigation into the cause of the proteinuria is warranted.Chronic kidney disease does not preclude the use of a statin.
However, the dose of some statins should be adjusted in
cases of moderate or severe renal insufficiency.25
Diabetes mellitus
A recent meta-analysis by Preiss et al in 2011 demonstrated
that statin therapy is associated with excess risk of devel-
oping diabetes mellitus.26 Justification for the Use of Sta-
tins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial found a 25% increase in dia-
betes risk in those assigned rosuvastatin.27 Another study
investigated the association between different statins and
new-onset diabetes. The study concluded that patients on
fluvastatin, lovastatin, and rosuvastatin were at lower risk
of new-onset diabetes, whereas patients who took pravas-
tatin were at greater risk. Simvastatin and atorvastatin had
a neutral effect.26 Although the risk of diabetes is increased
after the use of statins, riskebenefit analyses suggest that
statin treatment is favorable in high risk and secondary
prevention populations29 and that the cardiovascular and
mortality benefits of statin therapy exceed the diabetes
hazard, including in participants at high risk of developing
diabetes.30
The effect of statin therapy on the subsequent risk of
diabetes might be affected by the amount of drug-induced
cholesterol reduction. Endogenous cholesterol is critical for
the normal function of pancreatic b2 cells. Indeed, the
concentration of endogenous cholesterol can alter the
secretory function of these cells by regulating the func-
tional activity of calcium channels as well as insulin granule
mobilization and membrane fusion. Also, atorvastatin can
inhibit adipocyte maturation and the expression of insulin
sensitive glucose transporter (GLUT 4) in vitro.31 In
cultured pancreatic b cells, simvastatin (but not pravasta-
tin) reduced glucose-induced insulin secretion by attenu-
ating the glucose-induced increase in intracellular Ca2þ
concentration. This study suggests that statins may not only
impair insulin signaling but also insulin secretion.32
Clinicians should be vigilant about the drug-induced new
onset of diabetes in patients receiving intensive statin
therapy. Continuous monitoring of blood plasma glucose
levels during statin therapy and adjustment of dose as per
the biomedical results will help reduce the risks.
Neurologic manifestations
Statins are highly lipophilic and thus have greater potential
to cross the bloodebrain barrier and affect the central
nervous system. The first reports of neuropathy due to
treatment with statins appeared in 1994 followed by
several epidemiological studies demonstrating two to five
times increased risk of peripheral polyneuropathy in statin-
treated patients.33e35 Symptoms of statin-induced neu-
ropathy ranges from paresthesias, sensory loss, hyperes-
thesia of the extremities, areflexia, and muscle weakness
to memory loss in extreme cases. The risk of neuropathy
usually develops after long-term treatment and is depen-
dent on duration of statin use; i.e., the cumulative dose
rather than the daily dose. A study conducted in 2011 by
Otruba et al confirmed definite damage to peripheral
896 H.S. Grover et al.nerves in patients taking statins for more than 2 years.36
Symptoms of neuropathy are relieved by discontinuation
of treatment and any attempts to rechallenge with statins
are associated with their recurrence. Law and Rudnicka
estimate peripheral neuropathy caused by statins to have
an incidence of 12 per 100,000 persons.16 Data published by
the US FDA also admitted that statins may cause memory
loss, forgetfulness, and confusion span and that these
symptoms were reversible within a few weeks after the
discontinuation of the drug.Proinflammatory and immunogenic action of
statins
Statins have biphasic pro- and anti-inflammatory effects
that are mainly independent of their effects on blood
cholesterol and the anti-inflammatory effects related to
the mevalonic acid pathway. They may exert their proin-
flammatory effect directly via a mevalonate-independent
pathway. Gregoor in 2006 showed that fluvastatin induced
the release of interleukin-1b (IL-1b) and interferon-b by
human peripheral blood monocytes stimulated with Myco-
bacterium tuberculosis.37 Sun and Fernandes in 2003 re-
ported that lovastatin enhanced IL-6, IL-12, and tumor
necrosis factor-a (TNF-a) production by bone marrow-
derived dendritic cells.38 These results suggest that extra-
hepatic and direct effects of statins might play a poten-
tially undesirable role in patients who receive potent and
long-acting statins for a long time.
Also, long-term exposure to statins may be associated
with drug-induced lupus erythematosus and other autoim-
mune disorders such as dermatomyositis, polymyositis,
autoimmune hepatitis, pemphigoides, and hypersensitivity
pneumonitis. Fatal cases have been reported despite early
drug discontinuation and aggressive systemic immunosup-
pressive therapy.39Other AEs of statins
Pulmonary manifestation
Statin-induced interstitial lung disease (ILD) is a possible
newly recognized side effect of statin therapy.40 Also, there
is evidence of the progression of pulmonary fibrosis by
enhancing the secretion of inflammasome-regulated cyto-
kines, and numerous case reports have suggested that
statins may contribute to the development of various types
of ILD.41Ophthalmological manifestations
According to WHO criteria, statin therapy may cause
diplopia, ptosis, or ophthalmoplegia. This causality
assessment is based on the time relationship of drug
administration and adverse drug reaction development, the
multiple positive dechallenge and rechallenge reports, and
the plausible mechanism by which diplopia, ptosis, or
ophthalmoplegia may occur is myositis of the levator pal-
pebrae superioris muscles, extraocular muscles, or both.42Cancer risk
Increased breast cancer rates have been observed in
some statin trials.43 Preliminary results of the SEAS study
(Effect of Simvastatin and Ezetimibe on Clinical Outcomes
in Patients with Aortic Stenosis) indicated that cancer
rates were significantly higher in patients receiving sim-
vastatin in comparison to the placebo group.44 WOSCOPS,
a 5-year prospective trial of pravastatin in hypercholes-
terolemic men, showed an increase in incidence of
prostate cancer in the men who were randomized to
pravastatin therapy. This finding indicates that cancers
may become evident a decade or more after treatment
with statins.43 However, no difference was noted in
mortality from cancer in the simvastatin group and the
placebo group during the 10-year follow-up of the 4S
trial.44 Also, during the in-trial and 11-year post-trial
period of the HPS study, no significant differences were
recorded in cancer incidence at all sites or any particular
site, or in mortality attributed to cancer or to nonvas-
cular causes.53
Erectile dysfunction
Approximately 20e40% of men with diabetes and cardio-
vascular disease have low testosterone levels and hypo-
gonadism.47 Statins are commonly utilized in such
populations to reduce cardiovascular risk. Although low
testosterone levels and hypogonadism are not related to
erectile dysfunction (ED), it has been theorized that statins
can hamper adrenocortical function or steroidogenesis by
blocking cholesterol production. Alternatively, there is
reason to consider that statins may actually improve ED by
enhancing nitric oxide-mediated endothelial function.
Numerous studies have been performed to determine the
correlation between statin use and ED. However, there is no
concrete evidence to prove the relationship.48,49
AEs in the oral cavity
Cruz et al conducted a study in 2008 to investigate the side
effects of statins in the mouth cavity and to analyze the
symptoms after interruption of the treatment. A high per-
centage of oral symptoms such as dryness, itch, bitterness,
and cough were found to be associated to treatment with
statins and improvement occurred after temporary inter-
ruption of the treatment.50
Conclusions
Statins are now among the most frequently prescribed
medications and their use is likely to increase significantly
in the near future because they are now recommended also
for persons with average or low cholesterol levels, espe-
cially in secondary prevention. In most patients, statins are
safe and well tolerated. However, inhibition of the meval-
onate pathway gives rise to many potentially negative ef-
fects of statins. Although in all statin trials published to
date the net benefit far exceeds any potential risk, the
major drawback is that the patients in these randomized
Adverse effects of statins 897placebo-controlled trials are carefully selected, screened
for any contraindications, and systematically monitored.
Therefore, the amount of side effects in routine clinical
practice may be slightly higher. Moreover, statins are rec-
ommended as a lifelong therapy whereas most trials were
relatively short (< 5 years).54 With growing numbers of
patients taking these drugs for an increasing period of time,
awareness of statin AEs among physicians is vitally impor-
tant. This may lead to early recognition of the side effects,
enable more informed treatment decisions by patient and
provider, improve the quality of patient care, and reduce
patient suffering and morbidity.
The possible risks of widely prescribed statin therapy
should be decreased by administration of lower doses and
avoidance of risky combinations of drugs with interfering
metabolism via cytochrome P450. The role of a lipid
lowering diet plus exercise is indisputable and may support
lower doses of lipid lowering drugs or even lower use of
these drugs.55
The important challenge for future research is to
identify factors that predispose a given person to certain
side effects of statins. This would allow appropriate se-
lection for therapy of patients who may obtain the
greatest benefits and prevent or at least minimize the risk
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